1015 Capital Partners’s Quest Diagnostics DGX Stock Holding History

1015 Capital Partners’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.48K	Buy	7 +1	+17%	+$196	﹤0.01%	385
2026 Q1	$1.18K	Hold	6	–	–	﹤0.01%	396
2025 Q4	$1.04K	Buy	+6	New	+$1.09K	﹤0.01%	426

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

1015 Capital Partners's DGX Position: Q2 2026 in Review

1015 Capital Partners increased its Quest Diagnostics (DGX) stake by 17% in Q2 2026, buying an estimated $196 and bringing the position to 7 shares worth $1.48K. The position accounts for ﹤0.01% of the portfolio, ranked #385.

1015 Capital Partners first reported a position in DGX in Q4 2025 and has held it in 3 quarters since. 1,098 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

1015 Capital Partners held 7 shares of Quest Diagnostics worth $1.48K as of Q2 2026.
1015 Capital Partners bought 1 Quest Diagnostics share in Q2 2026, an estimated $196.
Quest Diagnostics made up ﹤0.01% of 1015 Capital Partners's portfolio in Q2 2026, its #385 holding.
1015 Capital Partners first reported a position in Quest Diagnostics in Q4 2025 and has held it in 3 quarters since.
1,098 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on 1015 Capital Partners's 13F filing for Q2 2026, filed 21 Jul 2026.